During the corresponding time, Xeris Biopharma Holdings Inc recorded a revenue increase by 28.74 % year on year, sequentially revenue grew by 10.79 %. While revenue at the Xeris Biopharma Holdings Inc 's corporate clients
Xeris Biopharma Holdings Inc's Comment on Sales, Marketing and Customers
The company has a commercial distribution agreement with a vendor for the products Recorlev, Gvoke, and Keveyis. Recorlev is marketed for endogenous Cushing’s syndrome and competes with therapies including Korlym by Corcept Therapeutics, Signifor and Signifor LAR by Recordati Rare Diseases Inc., and Isturisa also by Recordati. Off-label treatments in this area include ketoconazole, metyrapone, cabergoline, mitotane, and etomidate, some of which are marketed by HRA Pharma in Europe. Pipeline products for this indication are under development by Corcept Therapeutics Incorporated, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, Stero Therapeutics, and Lundbeck. Gvoke competes with Baqsimi by Amphastar, Zegalogue by Zealand Pharma, and emergency glucagon kits produced by Fresenius Kabi and other manufacturers. Keveyis faces competition from a generic version marketed by Torrent Pharmaceuticals Ltd., which has partnered with Cycle Pharmaceuticals Ltd to launch Ormalvi, a branded generic version of Keveyis.
: Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a forefront player in the biopharmaceutical sector, continues to demonstrate its commitment to enhancing patient lives through the development and commercialization of innovative therapies. As part of its strategic initiatives, the company will actively engage the investment community by participating in significant upcoming conferences. This article comprehensively reviews Xeris Biopharma s recent and forthcoming engagements, underscoring its growth orientation and sustained innovation in biopharmaceutical advancements.Xeris Biopharma Holdings, Inc. headquartered in Chicago, Illinois, is a biopharmaceutical company with a steadfast focus on improving patient ...
Xeris Biopharma Holdings Inc’s Comment on Sales, Marketing and Customers
The company has a commercial distribution agreement with a vendor for the products Recorlev, Gvoke, and Keveyis. Recorlev is marketed for endogenous Cushing’s syndrome and competes with therapies including Korlym by Corcept Therapeutics, Signifor and Signifor LAR by Recordati Rare Diseases Inc., and Isturisa also by Recordati. Off-label treatments in this area include ketoconazole, metyrapone, cabergoline, mitotane, and etomidate, some of which are marketed by HRA Pharma in Europe. Pipeline products for this indication are under development by Corcept Therapeutics Incorporated, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, Stero Therapeutics, and Lundbeck. Gvoke competes with Baqsimi by Amphastar, Zegalogue by Zealand Pharma, and emergency glucagon kits produced by Fresenius Kabi and other manufacturers. Keveyis faces competition from a generic version marketed by Torrent Pharmaceuticals Ltd., which has partnered with Cycle Pharmaceuticals Ltd to launch Ormalvi, a branded generic version of Keveyis.
Sources:
Xeris Biopharma Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Xeris Biopharma Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Xeris Biopharma Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
188.34 %